Moderna, mRNA
Digest more
Moderna (MRNA) stock surged 58% premarket following Phase 3 trial success showing its mRNA melanoma vaccine plus Keytruda ...
The late-stage melanoma trial with Merck’s Keytruda shows both lower recurrence and less spread, with no new safety ...
The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.
Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the ...
The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.
Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of ...
Shares of Moderna Inc MRNA had their best day in history as a public company this week, with the stock soaring on positive ...
Moderna MRNA stock fell 20%% to $138, compared with Wednesday’s close of $174.38. The decline followed a more than doubling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results